Ftse Mib
34.375,92
0,00%
DAX
18.590,89
-0,95%
S&P 500
5.631,22
0,28%
NASDAQ
18.472,57
0,40%
Bitcoin
63.989,59
-1,33%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Silo Pharma Inc (SILO) Silo Pharma Inc (SILO) Notizie

SILO

Silo Pharma (SILO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SILO
DataOraFonteTitoloSimboloCompagnia
21/11/202314:01GlobeNewswire Inc.Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSDNASDAQ:SILOSilo Pharma Inc
21/11/202301:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SILOSilo Pharma Inc
13/11/202323:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SILOSilo Pharma Inc
08/11/202314:11GlobeNewswire Inc.Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSDNASDAQ:SILOSilo Pharma Inc
23/10/202323:01Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SILOSilo Pharma Inc
23/10/202323:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SILOSilo Pharma Inc
16/10/202314:11GlobeNewswire Inc.Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid ArthritisNASDAQ:SILOSilo Pharma Inc
11/10/202314:35GlobeNewswire Inc.Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSDNASDAQ:SILOSilo Pharma Inc
10/10/202322:00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SILOSilo Pharma Inc
20/09/202314:28GlobeNewswire Inc.Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDANASDAQ:SILOSilo Pharma Inc
12/09/202314:50GlobeNewswire Inc.Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSDNASDAQ:SILOSilo Pharma Inc
31/08/202313:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SILOSilo Pharma Inc
10/08/202314:50GlobeNewswire Inc.Silo Pharma Engages Clarivate for Intellectual Property and Patent ManagementNASDAQ:SILOSilo Pharma Inc
08/08/202314:30GlobeNewswire Inc.Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related DisordersNASDAQ:SILOSilo Pharma Inc
29/06/202322:32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SILOSilo Pharma Inc
21/06/202315:00GlobeNewswire Inc.Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. PatentNASDAQ:SILOSilo Pharma Inc
13/06/202314:05GlobeNewswire Inc.Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant TherapeuticNASDAQ:SILOSilo Pharma Inc
02/06/202314:50GlobeNewswire Inc.Silo Pharma Announces Participation on Webull Corporate Communications Service PlatformNASDAQ:SILOSilo Pharma Inc
30/05/202315:00GlobeNewswire Inc.Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21NASDAQ:SILOSilo Pharma Inc
26/05/202322:20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SILOSilo Pharma Inc
09/05/202314:05GlobeNewswire Inc.Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s DiseaseNASDAQ:SILOSilo Pharma Inc
24/04/202314:15GlobeNewswire Inc.Silo Pharma to Present at Psychedelic Drug Development ConferenceNASDAQ:SILOSilo Pharma Inc
19/04/202315:00GlobeNewswire Inc.Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related DisordersNASDAQ:SILOSilo Pharma Inc
27/03/202315:00GlobeNewswire Inc.Silo Pharma Announces filing of Patent for Treatment of FibromyalgiaNASDAQ:SILOSilo Pharma Inc
15/03/202313:40GlobeNewswire Inc.Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for FibromyalgiaNASDAQ:SILOSilo Pharma Inc
14/02/202322:01Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SILOSilo Pharma Inc
13/02/202314:35GlobeNewswire Inc.Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’sNASDAQ:SILOSilo Pharma Inc
02/02/202314:50GlobeNewswire Inc.Silo Pharma Announces Expansion of Intellectual Property PortfolioNASDAQ:SILOSilo Pharma Inc
31/01/202313:45GlobeNewswire Inc.Silo Pharma Announces Stock Repurchase ProgramNASDAQ:SILOSilo Pharma Inc
10/01/202316:15GlobeNewswire Inc.Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on InflammationNASDAQ:SILOSilo Pharma Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SILO

La tua Cronologia

LSE
SUSW
Wld Sri Eur Acc
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network